News
MRNA
54.68
+0.77%
0.42
Why Is the SPY ETF Up Today, 4/16/2026?
TipRanks · 3h ago
OpenAI Launches New AI Model to Speed Up Drug Discovery
TipRanks · 4h ago
OpenAI launches AI model GPT-Rosalind for life sciences research
Reuters · 4h ago
Why Is Vanguard S&P 500 ETF (VOO) Up Today, 4/16/2026?
TipRanks · 10h ago
Assessing Moderna (MRNA) Valuation After Recent Share Price Momentum And Mixed Long Term Returns
Simply Wall St · 18h ago
Why Is the SPY ETF Up Today, 4/15/2026?
TipRanks · 1d ago
Why Is Vanguard S&P 500 ETF (VOO) Up Today, 4/15/2026?
TipRanks · 1d ago
Plus Therapeutics names Randy Goodman vice president of value strategy, HEOR
PUBT · 1d ago
White House reportedly eyeing former deputy surgeon general to lead CDC
Seeking Alpha · 1d ago
Moderna schedules first-quarter earnings call and webcast
PUBT · 1d ago
U.S. RESEARCH ROUNDUP-Autodesk, Citigroup, Wells Fargo
Reuters · 1d ago
Moderna: The Case For Staying On The Sidelines
Seeking Alpha · 1d ago
MODERNA <MRNA.O>: JEFFERIES RAISES TARGET PRICE TO $45 FROM $37
Reuters · 1d ago
Why Is the SPY ETF Up Today, 4/14/2026?
TipRanks · 2d ago
Moderna Inc. Stock Rises 4.3%, Outperforms Peers
Dow Jones · 2d ago
S&P 500 returns to positive territory and erases Middle East conflict losses
Seeking Alpha · 2d ago
Why Is Vanguard S&P 500 ETF (VOO) Up Today, 4/14/2026?
TipRanks · 2d ago
U.S. RESEARCH ROUNDUP-Biogen, Equinix, Revolution Medicines
Reuters · 2d ago
MODERNA <MRNA.O>: LEERINK PARTNERS RAISES TARGET PRICE TO $21 FROM $12
Reuters · 2d ago
Why Is the SPY ETF Up Today, 4/13/2026?
TipRanks · 3d ago
More
Webull provides a variety of real-time MRNA stock news. You can receive the latest news about Moderna through multiple platforms. This information may help you make smarter investment decisions.
About MRNA
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).